Sigachi Industries Limited
NSE: SIGACHI · Pharmaceuticals
Snapshot
Unlock Sigachi Industries Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sigachi Industries Limited is a manufacturer of microcrystalline cellulose and cellulose powder, primarily serving the pharmaceutical, nutraceutical, food, and chemical sectors. The company operates from its base in Hyderabad and maintains both domestic and international market operations.
Business Model
The company generates revenue through the manufacturing and sale of cellulose-based excipients and specialty chemicals. It leverages its technical expertise to supply essential ingredients to diverse industrial applications globally.
Growth Outlook
Growth is driven by the increasing demand for high-quality pharmaceutical excipients and the expansion of the company's product portfolio into nutraceutical and food applications. Continued focus on export markets provides additional scalability for its manufacturing operations.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of cellulose-based raw materials can significantly impact the company's operating margins.
- Regulatory Compliance. As a supplier to the pharmaceutical industry, the company must adhere to stringent global quality standards and regulatory audits.
- Foreign Exchange Risk. Exposure to international markets subjects the company to currency fluctuations that may affect export profitability.
- Competitive Intensity. The specialty chemicals sector is highly competitive, requiring continuous investment in process efficiency and product innovation.
Start your research today
Unlock AI insights, financials, peers and live data on Sigachi Industries Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹471 Cr
TTM · consolidated
NET PROFIT
₹26 Cr
TTM · consolidated
EPS
₹0.67
TTM · consolidated
RETURN ON EQUITY
4.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.0%
TTM · consolidated
P/E
51.9x
Q1 FY27 · consolidated
EV/EBITDA
28.0x
Q1 FY27 · consolidated
EBITDA MARGIN
10.9%
TTM · consolidated
NET PROFIT MARGIN
6.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sigachi Industries LimitedSIGACHI | ₹1,327 Cr | 51.85 | 28.02 | -9.6% | 10.9% | 4.7% | 6.0% | +11.0% |
Fermenta Biotec.FERMENTA | ₹1,467 Cr | 19.95 | 12.64 | 11.9% | 23.3% | 19.0% | 26.1% | +49.6% |
Amrutanjan Health Care LimitedAMRUTANJAN | ₹1,461 Cr | 27.07 | 16.03 | 10.7% | 17.7% | 15.5% | 20.2% | -30.9% |
Lincoln Pharmaceuticals LimitedLINCOLN | ₹1,243 Cr | 12.89 | 8.53 | 10.2% | 20.7% | 13.5% | 17.5% | +12.9% |
KopranKOPRAN | ₹1,123 Cr | 44.98 | 20.09 | 12.0% | 9.1% | 4.8% | 7.7% | +37.7% |
Themis MedicareTHEMISMED | ₹1,109 Cr | 27.75 | -36.75 | -12.8% | -9.9% | 10.0% | 11.3% | +20.2% |
As of Q1 FY27
Financials
Sigachi Industries Limited
NSE: SIGACHI · Pharmaceuticals
Snapshot
Unlock Sigachi Industries Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sigachi Industries Limited is a manufacturer of microcrystalline cellulose and cellulose powder, primarily serving the pharmaceutical, nutraceutical, food, and chemical sectors. The company operates from its base in Hyderabad and maintains both domestic and international market operations.
Business Model
The company generates revenue through the manufacturing and sale of cellulose-based excipients and specialty chemicals. It leverages its technical expertise to supply essential ingredients to diverse industrial applications globally.
Growth Outlook
Growth is driven by the increasing demand for high-quality pharmaceutical excipients and the expansion of the company's product portfolio into nutraceutical and food applications. Continued focus on export markets provides additional scalability for its manufacturing operations.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of cellulose-based raw materials can significantly impact the company's operating margins.
- Regulatory Compliance. As a supplier to the pharmaceutical industry, the company must adhere to stringent global quality standards and regulatory audits.
- Foreign Exchange Risk. Exposure to international markets subjects the company to currency fluctuations that may affect export profitability.
- Competitive Intensity. The specialty chemicals sector is highly competitive, requiring continuous investment in process efficiency and product innovation.
Start your research today
Unlock AI insights, financials, peers and live data on Sigachi Industries Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹471 Cr
TTM · consolidated
NET PROFIT
₹26 Cr
TTM · consolidated
EPS
₹0.67
TTM · consolidated
RETURN ON EQUITY
4.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.0%
TTM · consolidated
P/E
51.9x
Q1 FY27 · consolidated
EV/EBITDA
28.0x
Q1 FY27 · consolidated
EBITDA MARGIN
10.9%
TTM · consolidated
NET PROFIT MARGIN
6.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27